REVLIMID ® (lenalidomide) is indicated as maintenance therapy in patients with multiple myeloma (MM) following autologous
hematopoietic stem cell transplantation (auto-HSCT)
REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of
controlled clinical trials
REVLIMID is only available through a restricted distribution program, REVLIMID REMS ®
Most Patients With MM
Achieve a Response
Following Auto-HSCT—
What Comes Next?
REVLIMID maintenance therapy can help your patients
maintain their response
Lenalidomide (REVLIMID) is the only FDA-approved and only National Comprehensive
Cancer Network ® (NCCN ® ) Category 1 recommended therapy for post auto-HSCT
maintenance in patients with multiple myeloma 3,4
WARNING: EMBRYO-FETAL TOXICITY, HEMATOLOGIC TOXICITY, and VENOUS and
ARTERIAL THROMBOEMBOLISM
See full prescribing information for complete boxed warning.
EMBRYO-FETAL TOXICITY
• Lenalidomide, a thalidomide analogue, caused limb abnormalities in a developmental monkey study similar to
birth defects caused by thalidomide in humans. If lenalidomide is used during pregnancy, it may cause birth defects
or embryo-fetal death.
• Pregnancy must be excluded before start of treatment. Prevent pregnancy during treatment by the use of two reliable methods
of contraception.
REVLIMID is available only through a restricted distribution program called the REVLIMID REMS ® program.
HEMATOLOGIC TOXICITY. REVLIMID can cause signifi cant neutropenia and thrombocytopenia.
• For patients with del 5q myelodysplastic syndromes, monitor complete blood counts weekly for the fi rst 8 weeks and
monthly thereafter.
VENOUS AND ARTERIAL THROMBOEMBOLISM
• Signifi cantly increased risk of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as risk of myocardial infarction and
stroke in patients with multiple myeloma receiving REVLIMID with dexamethasone. Anti-thrombotic prophylaxis is recommended.
NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their
application or use in any way.
Please see Important Safety Information and Brief Summary, including Boxed WARNINGS, on the following pages.